Xlear Admits Referencing Research, Avers Studies Support Saline Nasal Spray’s COVID-19 Efficacy
Firm responds to a complaint DoJ filed for FTC. Founder and president Nathan Jones continues criticism that FTC is attempting to silence research-backed advertising for alternatives to pharmaceuticals public health agencies promote for preventing or treating COVID-19.
You may also be interested in...
“Pharmaceuticals have their place, and many do wonderful things for health, but the science of nasal hygiene is clear,” says marketing director Joel Melton.
COVID-19 False Advertising Wasn't Any Falser Than During Other Public Health Crises; The Internet Was The Difference Maker
The types of unsupported claims made during the COVID-19 pandemic have not been so different from those seen before when the US faced public health emergencies. But this time advertisers' digital capabilities turned up the volume on false and unsubstantiated claims about COVID cures and the like, says Rich Cleland, FTC Consumer Protection Bureau attorney.
While types of unsupported claims were no different than those advertisers made when US was hit it by other widespread health emergencies, digital capabilities made advertisers’ response to COVID-19 different, says Rich Cleland, FTC Consumer Protection Bureau attorney.